MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1161/jaha.125.042530

Медицинская библиотека · Journal of the American Heart Association · 2025

Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study.

Sperry Brett W, Masri Ahmad, Soman Prem, Ejaz Ain U, Bhattacharya Priyanka, Medoff Brent, Chandrashekar Pranav, Ives Lauren, Mirabal Santos Alfonsina, Teruya Sergio L, Wu Yanjun, Zhao Yuanzi, Wang Xiaofeng, Maurer Mathew S, Hanna Mazen

СтатьяМногоцентровое исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Diagnostic rates of transthyretin cardiac amyloidosis have increased due to growing awareness, noninvasive diagnoses, and treatments that improve morbidity and mortality. We sought to investigate real-world trends in baseline characteristics and survival in the United States.

METHODS

Patient-level data at 5 cardiac amyloid referral centers were used, and mortality (defined as death or surgical heart failure therapies) was compared by eras (pre-2010, 2010-2013, 2014-2017, and 2018-2021) and National Amyloidosis Center (NAC) stage.

RESULTS

Among 1165 subjects, diagnosis of transthyretin cardiac amyloidosis in a more recent era was associated with older age, white race, wild-type disease, and tafamidis treatment (P<0.001). NAC stage was similar (P=0.866) while Columbia stage was lower (P=0.006) in recent eras, driven by lower New York Heart Association class and loop diuretic dose. Over a median follow-up of 44.5 (interquartile range, 21-60) months, 630 subjects died, and diagnosis in a more recent era was associated with a lower mortality. Tafamidis was protective (hazard ratio [HR], 0.71; P=0.002), and NAC stage >1 portended an increased risk of death (stage 2: HR, 2.00; P<0.001; stage 3: HR, 4.02; P<0.001). There were interactions between tafamidis and both NAC stage and age, suggesting that the beneficial effects of tafamidis were attenuated at higher NAC stages (stage 2: P=0.041; stage 3: P=0.012) and older age (P=0.001).

CONCLUSIONS

In this multicenter study of patients seen at referral centers for transthyretin cardiac amyloidosis, diagnosis in a more recent era was associated with improved survival, while tafamidis benefits were attenuated by disease severity and older age. Significant residual mortality risk remains in treated patients at higher disease stages.

Для цитирования: Sperry Brett W, Masri Ahmad, Soman Prem, Ejaz Ain U, Bhattacharya Priyanka, Medoff Brent, Chandrashekar Pranav, Ives Lauren, Mirabal Santos Alfonsina, Teruya Sergio L, Wu Yanjun, Zhao Yuanzi, Wang Xiaofeng, Maurer Mathew S, Hanna Mazen. Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study.. Journal of the American Heart Association. 2025. DOI: 10.1161/jaha.125.042530.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.